Molecular genetics of lung cancer in people who have never smoked
- PMID: 18598932
- DOI: 10.1016/S1470-2045(08)70174-8
Molecular genetics of lung cancer in people who have never smoked
Abstract
Lung cancer is a major cause of cancer-related mortality in the USA, and tobacco smoke is the major risk factor for this disease. However, many patients with lung cancer have never smoked (never smokers). Patients with lung cancer who have never smoked are more likely to have mutations in epidermal growth factor receptor (EGFR) tyrosine kinase and have better response to its inhibitors than do patients with tobacco-associated lung cancer. Furthermore, the prevalences of mutations in KRAS and P53 differ for patients with lung cancer who have never smoked and those with tobacco-associated lung cancer. Genetic mutations seem to be more common in patients with tobacco-associated lung cancer than in never smokers. Current evidence indicates that the two types of lung cancer are biologically distinct. Here, we review published studies of the molecular genetics of lung cancer in never smokers and identify the specific differences from tobacco-associated lung cancer.
Similar articles
-
Lung cancer in never smokers: a review.J Clin Oncol. 2007 Feb 10;25(5):561-70. doi: 10.1200/JCO.2006.06.8015. J Clin Oncol. 2007. PMID: 17290066 Review.
-
TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.Cancer Res. 2005 Jun 15;65(12):5076-83. doi: 10.1158/0008-5472.CAN-05-0551. Cancer Res. 2005. PMID: 15958551
-
p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer.Cancer Res. 2000 Jun 1;60(11):2906-11. Cancer Res. 2000. PMID: 10850436
-
Lung cancer in never smokers.Future Oncol. 2011 Oct;7(10):1195-211. doi: 10.2217/fon.11.100. Future Oncol. 2011. PMID: 21992731 Review.
-
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.J Clin Oncol. 2006 Apr 10;24(11):1700-4. doi: 10.1200/JCO.2005.04.3224. Epub 2006 Feb 27. J Clin Oncol. 2006. PMID: 16505411
Cited by
-
Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status.PLoS One. 2015 May 22;10(5):e0127600. doi: 10.1371/journal.pone.0127600. eCollection 2015. PLoS One. 2015. PMID: 26001082 Free PMC article.
-
Smoking habit and chemo-radiotherapy and/or surgery affect the sensitivity of EGFR plasma test in non-small cell lung cancer.BMC Res Notes. 2020 Aug 3;13(1):367. doi: 10.1186/s13104-020-05209-9. BMC Res Notes. 2020. PMID: 32746896 Free PMC article.
-
Molecular biology of lung cancer.J Thorac Dis. 2013 Oct;5 Suppl 5(Suppl 5):S479-90. doi: 10.3978/j.issn.2072-1439.2013.08.03. J Thorac Dis. 2013. PMID: 24163741 Free PMC article. Review.
-
The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response.Adv Exp Med Biol. 2020;1219:311-333. doi: 10.1007/978-3-030-34025-4_16. Adv Exp Med Biol. 2020. PMID: 32130706 Review.
-
Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.J Thorac Dis. 2014 Oct;6(Suppl 5):S502-25. doi: 10.3978/j.issn.2072-1439.2014.05.19. J Thorac Dis. 2014. PMID: 25349702 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous